Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01557244 · ClinicalTrials.gov registry record · Phase 3
A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 181
- Enrollment target
NCT01557244 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 181 participants.
The verdict
NCT01557244, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 181 participants
- Enrollment target
Study Summary
The objective of the study is to find out if the medicine fesoterodine is a useful treatment in children with bladder muscle overactivity caused by a neurological condition. Children will be aged 6 to 17 years old. This is done by finding out how well it works, what the body does to fesoterodine, what side effects are experienced and the safety of fesoterodine. It will be compared with the medicine oxybutynin, which is already available for treating the condition.
Interventions
- DRUG Oxybutynin
- DRUG Fesoterodine PR 4 mg
- DRUG Fesoterodine PR 8 mg
- DRUG Fesoterodine PR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2012-07-02 |
| Est. Completion | 2020-02-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01557244
The ClinicalTrials.gov registry entry for NCT01557244 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Oxybutynin is the first listed.
NCT01557244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01557244 about?
NCT01557244 is a clinical study titled "A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition". The objective of the study is to find out if the medicine fesoterodine is a useful treatment in children with bladder muscle overactivity caused by a neurological condition. Children will be aged 6 to 17 years old. This is done by finding out how well it works, what the body does to fesoterodine, wh...
What is the current status of trial NCT01557244?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 181 participants. The study started on 2012-07-02. Estimated completion is 2020-02-13.
What interventions are being tested in trial NCT01557244?
The interventions under investigation include: Oxybutynin (DRUG), Fesoterodine PR 4 mg (DRUG), Fesoterodine PR 8 mg (DRUG), Fesoterodine PR (DRUG).
Who is sponsoring clinical trial NCT01557244?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.